Glioblastoma (GBM) is the most aggressive and common malignant tumor in the central nervous system. Current therapeutic regimens, including surgical resection combined with external radiation and chemotherapy, are insufficient to treat GBM. Three important factors account for the lack of efficacy. GBM can infiltrate into surrounding tissues and makes complete resection impossible. Besides, the blood-brain barrier usually prevents therapeutic agents and limits the chemotherapy efficacy. In addition, tumor cells can develop resistance to therapeutic agents. Convection-enhancement delivery (CED) is the technique that is expected to improve the efficacy of chemotherapy in GBM. The systematic overview of CED in the treatment of GBM is based on the researches from 2000 to 2020, involving in the technical basis of CED, animal models, chemotherapeutic agents, tracing, and clinical research. The results show that CED technology has advantages including overcoming the blood-brain barrier, inducing the immune reaction in the tumor, and reducing systemic toxicity. In the future, the mechanism on transportation and metabolism of drugs in the extracellular space and the development of chemotherapy-tracing multimodal nano-agents should be warranted.